Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium That Supports P300 KAT Inhibition in HPV-Driven Tumors
Piper Sandler Maintains Kronos Bio(KRON.US) With Buy Rating, Maintains Target Price $6
Piper Sandler Remains a Buy on Kronos Bio (KRON)
Express News | Kronos Bio Inc - to Initiate Ind-Enabling Studies of KB-7898 in Q4 2024
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjgren's Disease
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease